3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 4 areas
1
News (30d)
National Institutes of Health is a company with 3 orphan drug designations across 3 rare diseases. 1 news article in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| glioblastoma | cediranib | Des.TrialAppr. |
| malignant mesothelioma | Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin | Des.TrialAppr. |
| ovarian carcinoma | Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
1
avg importance: 30
0
affecting portfolio
0% of portfolio targets high unmet need diseases
2
overlap in 2+ diseases
0/3
candidate diseases
1
avg importance: 30
0
affecting portfolio